respectively) in DMSO were diluted to 4 % (w/v) in FR shortly before incubation with the oocytes (final concentrations 110 µM and 80 µM, respectively). After incubation, the oocytes were washed for 3 min with FR, for 1 min in 1 mM glycine-containing FR, and again with FR (3 min) before recording the agonist response as detailed above; only stable and reproducible responses were considered. Inactivation experiments were repeated for each mutant-drug combination; a reduction in response >15 % was taken as a significant inactivation, as variations between experiments were smaller. The same protocol was applied in protection experiments, in which 1 mM glycine or 10 mM L-701,324 were included during the incubation; under these conditions, the mutant receptors were fully protected from inactivation. RESULTS 
AND DISCUSSION

Model-assisted Design of Cysteine Mutants--
The ligand-binding segments S1 and S2 of NR1 present in the glycine binding recombinant NR1 fusion protein (21) display a sequence identity of 22 % with the glutamate binding domains (S1-S2) of the AMPA receptor (28) . The polypeptide backbone of the NR1 glycine binding site was therefore modeled after the crystal structure (accession number 1GluR2) of the AMPA receptor binding region (28) . The resulting model is presented in Fig. 2 , panel A. It includes segments S1 and S2 of the NR1 polypeptide, with the same sequence of secondary structure elements (helices, strands and loops) as in the GluR2 template (28) . Like in bacterial amino-acid binding proteins (31) , segments S1 and S2 form the globular lobes 1 and 2, which are connected by two hinge regions (see also Ref. 7) . The lobes are separated by a central cleft that provides the ligandbinding pocket and is lined by loop regions 385-390, 463-467, 500-505, 694-696 and 714-717. These loops harbour determinants of glycine site pharmacology (15, 16, 18, 19, 21) .
Computational docking of the glycine site antagonist L-701,324 resulted in two possible orientations (Fig. 2, panel B) . The first predicted docking mode for L-701,324 ressembled that of the AMPA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the GluR2 S1-S2 crystal, with the quinoline ring's 2-carbonyl group pointing towards the guanidinium group of R505, and the heterocyclic N-atom towards the backbone carbonyl of antagonist and the energy DF predicted to stabilize binding (26 kcal/mole) were the same in both modes of docking.
In order to test which of these orientations is used by L-701,324, we substituted residues I385, Q387, E388, F390, T500, I501, N502, S695, A696, D714 and V717 of the NR1 subunit by cysteines. All these residues are predicted to contact the reactive antagonists in their different docking orientations (Fig. 2) . The substituted NR1 polypeptides were then coexpressed with the wild-type NR2B subunit in Xenopus oocytes, and the resulting receptors examined for their reactivities towards the cysteine-reactive antagonists by monitoring the recovery of agonist-induced currents after incubation with these reagents.
Irreversible Inactivation of Mutant Receptors by Cysteine-Reactive Antagonists--The three
reactive ligands used in this study, 7-isothiocyanate-4-hydroxy-3-(3-phenoxyphenyl)quinolin-
]acetamide (7-CAA), and 7-chloro-4-hydroxy-3-(isothiocyanatophenyl)quinolin-2(1H)-one (m 1 -NCS) ( Fig. 1) , were selected out of twelve compounds described previously, on the basis of their high reactivity towards cysteine, their stability in frog Ringer's solution, and their affinity for wild-type NMDA receptors (27): 7-CAA, 7-NCS and m 1 -NCS bind reversibly to rat brain membranes with K i s of ca. 280, 64 and 48 nM, respectively (27) , as Xenopus oocytes injected with wild-type NR1 and NR2B cRNAs (15) (16) were blocked by >95% upon incubation with saturating concentrations (50 µM) of these reactive antagonists but fully recovered after a 3-5 min washout as reported (27) . In contrast, when cysteinemutant receptor expressing Xenopus oocytes were incubated with these ligands under identical conditions, inhibition of agonist-induced currents often could not be reversed upon prolonged washing for up to 20 min with some of the mutants. This is illustrated in Fig. 3 .
Panel A shows a typical experiment with mutant V717C. Incubation with 7-CAA irreversibly reduced the current by ca. 70% (top), indicating that the cysteine residue introduced had reacted with the covalent antagonist; this inhibition of the current response was not observed when L-701,324 was added to 7-CAA during the incubation (bottom). Notably, this irreversible inhibition of the glycine currents frequently displayed high chemical selectivity. (27) . With mutated receptors subject to inactivation by these ligands, precise affinity estimates cannnot be obtained. Different lines of evidence, however, indicate that the inactivations observed here reflect covalent bond formation with the mutated position, and that they occured within the ligand-binding site: i) the substantial inactivation of cysteine-substituted but not wild-type receptors seen upon incubation with our reactive ligands is consistent with the newly introduced cysteines constituting the reagents` target residues; ii) saturating concentrations of glycine protected the cysteine mutants from inactivation, as predicted for covalent bond formation within the glycine binding site; and iii) the ligand and receptor concentrations used in our inactivation experiments were far too low to support a bi-molecular reaction mechanism; in model reactions (27) , millimolar concentrations of reactive analogue and of free cysteine were required to observe a reagent half-life of 20 min. We therefore conclude that the receptor-inactivating coupling reactions occurred within the binary receptor-ligand complex.
Selectivity of Mutant Receptor Inactivations by Cysteine-Reactive Antagonists--A systematic
analysis of the inactivation patterns obtained for the 14 cysteine mutants upon incubation with the different reactive antagonists (Fig. 4) revealed that 7-NCS inactivated mutants Q387C, T500C and A696C but none of the other mutant receptors. In contrast, 7-CAA carrying a different reactive group at the same position as 7-NCS caused strong inactivation of mutants I385C, E388C, T500C and V717C but not of Q387C and A696C or any of the other mutants tested. Both ligands failed to inactivate substitution F390C, although this residue is located in close vicinity to reactive positions. N502C was the only mutant found to be significantly inactivated out of the six mutants incubated with derivative m 1 -NCS (Fig. 4) . These results highlight the high selectivity of mutant receptor inactivations and are summarized in Table 1 .
We conclude from these data that ligands 7-CAA and 7-NCS react selectively and differentially with cysteine residues introduced into the loop between positions 385 and 390, and, on the opposite side of the central cleft, into loops 695-696 and 714-717. In addition, of the cysteine substitutions in the T500-N502 loop region, T500C but not I501C or N502C
were accessible to 7-NCS and 7-CAA, whereas m 1 -NCS reacted solely with mutant N502C but not with T500C. Finally, we were unable to observe receptor inactivation with the NR1 substitutions Q518C, G519C and V771C, and therefore these mutants were not further analyzed. In summary, each derivative reacted site-specifically and selectively with cysteines introduced in loops predicted to line the glycine binding pocket in our model.
Implications for Antagonist Docking in the Glycine
Binding Site--The inactivation patterns described above allowed to define the mode of antagonist docking in the modeled glycine binding pocket of the NMDA receptor. All our data are consistent with an antagonist docking position resembling that of CNQX in the glutamate binding pocket of the AMPA receptor GluR2 and exclude the alternative positioning suggested by our molecular simulations. This conclusion is based on the following considerations. First, the covalent antagonists carrying reactive substituents at the 7-position of the quinoline ring system inactivated mutant receptors with cysteine residues at positions 385-390, 500, 696, and 717 (Table 1 ). This broad reactivity pattern can be explained by the reactive groups of both 7-NCS and 7-CAA displaying high rotational mobility, thus allowing alkylation of multiple cysteine-substituted residues by the docked ligand. In addition, the nature of the reactive group, in particular the distance of its electrophilic center from the quinoline ring, was found to critically influence inactivation reactions. As shown in Figure 5a , b, all target residues mentioned above were predicted to be available to modification by 7-NCS and 7-CAA from the same docking position of the quinoline ring which hence defines its positioning within the binding pocket. Accordingly, the 7-substituents of the quinoline ring are oriented towards the I385-F390 loop of lobe 1 but may in addition interact with positions A696 and V717 of lobe 2 on the opposite edge of the binding cleft. In this area, the distance between the two lobes, represented by loop 385-391 on lobe 1 and by loops 694-698 and 714-718 on lobe 2, is less than twice the length of the acetamide group, i.e. 5-8 Å in our model. This is consistent with previous ligand modification and site-directed mutagenesis studies. Substitutions on the quinoline ring system have been found to drastically reduce binding affinity (32) (33) (34) , and mutations in the surrounding loops are known to lower glycine efficacy (15) . 
Ligand-Neighbouring Residues Identified by Chemical Coupling--Among the seven
"positive" residues (see table 1), only Q387 (15) and A696 (19, 37) have been previously shown by point mutation to contribute to glycine binding. In our experiments, receptors generated from NR1 mutants Q387C, T500C and A696C were found to display 100-1000 fold lower apparent glycine affinities than the wild-type protein (Table 1 ). This and their inactivation by 7-NCS indicates that the bound ligand must be close to these residues in the mutant receptors. Due to the large shift in glycine affinities seen with these mutants, we cannot, however, exclude that the structure of the ligand binding site may have been altered upon mutation, and therefore cannot infer proximity for the wild-type binding pocket. The previously described substitution N502T has no effect on glycine affinity (15) . Also, for mutants I385C, E388C, N502C and V717C, the EC 50 values for glycine were found to be similar to that of the wild-type receptor (Table 1) . Consequently, we propose that the structure of the binding site was not significantly modified by these latter substitutions, and therefore these positions should be at short distance from the bound ligand even in the wild-type protein. The results observed with N502C illustrate that mutant pharmacology alone may fail to identify a binding site residue. Conversely, mutants F390C and D714C did not react with our probes (whilst the neighbouring substitutions E388C and V717C did), although mutation of these positions has been shown to alter glycine EC 50 values (15, 18) . Presumably this reflects an only indirect contribution of the respective side chains to the structure of the binding pocket. For D714, different substitutions of this residue have been found to decrease the affinities of the agonists glycine and D-serine and to increase the affinity of the antagonist 5,7-dichlorokynurenate (18) . Since these substitutions also modified the efficacy of partial agonists, the opposite changes in glycine and 5,7-dichlorokynurenate affinities could reflect a role of position 714 in channel gating rather than in ligand binding (18) . Accordingly, D714C
would not be expected to react with our probes. This further underlines that site-directed mutagenesis must be interpreted with caution to predict ligand-receptor interactions (38).
Towards the characterization of subtype determinants--In this study, we have used cysteine mutants as chemical sensors to identify amino-acid side chains of the NR1 polypeptide which interact with reactive glycine site antagonists of the NMDA receptor. Our data extend conclusions derived from site-directed mutagenesis and show that structural models can be reliably probed using engineered selective chemical coupling reactions (25) . From two predicted modes of ligand docking in the modeled glycine binding site, the correct one could be unequivocally assigned. In addition, amino acid positions identified by site-directed mutagenesis as being crucial for agonist binding could be subclassified further into ligandreactive and non-reactive residues, i.e. putative binding and conformationally important sidechains. That mutational approaches cannot easily discriminate residues whose substitution affects ligand binding via conformational changes from side-chains that are directly implicated in ligand interaction has been emphasized in a previous theoretical analysis (38).
Interlobe closure upon agonist binding is thought to be crucial for glutamate receptor activation (39). In our previous studies, agonist docking in the central cleft was proposed to cause closure of the binding pocket by interactions with both lobes, whilst antagonists were suggested to stabilize its open conformation by binding predominantly to lobe 1 (7, 15) . Here, the 7-position of the quinoline ring of the glycine site antagonist was found to react with substituted cysteines in both lobes, across the central cleft. This is consistent with recent Xray crystallographic data on differently liganded states of the GluR2 S1-S2 glutamate binding site, in which antagonists were found to prevent interlobe closure (39). As established here, the quinoline ring of antagonists at this site is docked in the narrow part of the binding cleft close to residues of both lobes. We propose that this type of interaction may provide for antagonist blocking of interlobe closure.
The pharmacology of the glycine site of the NMDA receptor has been found to depend on the co-assembled NR2 subunit isoform, although this site is located on the NR1 polypeptide.
In heterologous expression systems, the subunit combinations NR1-NR2A and NR1-NR2B display "antagonist-" and "agonist-preferring" properties, respectively (8, 9) . Interestingly, mutant NR1(A696C) has an affinity for glycine similar to that of the wild-type subunit when co-assembled with NR2A (19), while its EC 50 value is increased by 2 orders of magnitude when combined with NR2B (Table 1) . In protection experiments, this mutant appears to discriminate agonists from antagonists (19). Extending our approach to different NR1/NR2 subunit combinations may result in different patterns of inactivation, thus disclosing the subtle structural differences which underlie the distinct pharmacologies of the different NMDA receptor subtypes. This appears particularly challenging in case of the newly discovered NR3B subunit which co-assembles with NR1 to form channels which are activated by glycine alone (40). Notably, these NR1/NR3B channels are antagonized by 5,7-dichlorokynurenate but also by D-serine which is a glycine-site agonist at all other NMDA receptors (14) . As the NR3B subunit is prominently expressed in motor areas of the brain and spinal cord (40), some motor pathways might be activated by glycine rather than glutamate (41). Thus, antagonists selective for the NR3B glycine binding site could help to prevent the progressive excitotoxic degeneration of spinal motoneurons that occurs in amyotrophic lateral sclerosis (42).
In conclusion, our data show that our method of site-directed chemical coupling can be used 
